Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1 Most recently, immunotherapy, in the form of immune checkpoint inhibitors, has been successful in the treatment of a variety of advanced common solid tumours, […]
No takes yet. Share an insight, caveat, or question.
Randhawa et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: